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ULTRA-SMALL RNAS AS TOLL-LIKE 
RECEPTOR-3 ANTAGONISTS 
This application is a national stage of PCT International 
Application No. PCT/US2009/001106, ?led Feb. 20, 2009, 
Which claims priority under 35 USC §119 to US. Provi 
sional Application No. 61/030,487, ?led Feb. 21, 2008, the 
entire disclosure of Which is herein expressly incorporated by 
reference. 
The instant application contains a Sequence Listing Which 
has been submitted via EFS-Web and is hereby incorporated 
by reference in its entirety. 
FIELD OF THE INVENTION 
The present invention relates to the ability of ultra-small 
RNAs to act as toll-like receptor-3 (TLR3) antagonists. 
BACKGROUND 
The macula is the part of the retina Which is responsible for 
central vision. Age-related macular degeneration is a chronic 
eye disease that occurs When tissue in the macula deteriorates. 
Macular degeneration affects central vision, but not periph 
eral vision. Macular degeneration is the leading cause of 
severe vision loss in people age 60 and older. 
There are tWo forms of age-related macular degeneration: 
dry and Wet. Dry macular degeneration is the most common 
type of macular degeneration and occurs When cells of the 
macula sloWly begin to break doWn. YelloW deposits called 
“drusen” form under the retina betWeen the retinal pigmented 
epithelium (RPE) and Bruch’s membrane, Which supports the 
retina. The drusen deposits are debris associated With com 
promised cell metabolism in the RPE. Eventually there is a 
deterioration of the macular regions associated With the 
drusen deposits resulting in a loss of central vision. 
Wet macular degeneration occurs When abnormal blood 
vessels groW behind the macula. These vessels are fragile and 
can leak ?uid and blood, Which result in scarring of the 
macula and raise the potential for rapid, severe damage. 
Bruch’s membrane breaks doWn, usually near drusen depos 
its. This is Where neW blood vessel groWth, or neovascular 
iZation, occurs. Central vision can become distorted or lost 
entirely in a short period of time, sometimes Within days. Wet 
macular degeneration is responsible for about 10 percent of 
the cases of age-related macular degeneration, but it accounts 
for about 90 percent of the cases of legal blindness. 
SUMMARY OF THE INVENTION 
In one aspect the present invention relates to a method of 
treating or preventing macular degeneration. The method 
comprises exposing a retinal or choroidal cell to a toll-like 
receptor 3 (TLR3)-antagonistic effective amount of a double 
stranded RNA of 22 nucleotides or shorter length Whichbinds 
to but does not activate the activity of a TLR3. 
In yet another aspect, the present invention relates to a 
method of treating or preventing a disease or disorder asso 
ciated With activation of TLR3. The method comprises expos 
ing a subject in need thereof to a toll-like receptor 3 (TLR3) 
antagonistic effective amount of a double-stranded RNA of 
22 nucleotides or shorter length Which binds to but does not 
activate the activity of a TLR3 
In another aspect, the present invention relates to a com 
position for the treatment or prevention of macular degenera 
tion. The composition comprises a sequence-nonspeci?c or 
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sequence-speci?c double-stranded RNA of 22 nucleotides or 
shorter length Which binds to but does not activate the activity 
of a TLR3. 
In yet another aspect, the present invention relates to a 
method for increasing the speci?city of a desired siRNA 
target knockdoWn. The method comprises administering an 
amount of a target siRNA su?icient to knockdoWn a target 
gene and an amount of a double stranded RNA of 22 nucle 
otides or less Which prevents the target siRNA from activating 
TLR3. 
In still another aspect the present invention relates to a 
method for screening for a compound that antagonizes TLR3. 
The method comprises contacting TLR3 or binding fragment 
thereof With a test compound, and determining if a complex is 
formed betWeen TLR3 or binding fragment thereof and the 
test compound. 
Other systems, methods, features and advantages of the 
present invention Will be or become apparent to one With skill 
in the art upon examination of the folloWing draWings and 
detailed description. It is intended that all such additional 
systems, methods, features and advantages be included 
Within this description, be Within the scope of the present 
invention, and be protected by the accompanying claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates the effect of poly (I:C) and poly (dI:dC) 
on survival of human retinal pigmented epithelial cells. 
FIG. 2 shoWs the effect of intravitreous administration of 
poly (I:C) on survival of retinal pigmented epithelial cells 
from Wild-type and Tlr3_/_ mice. 
FIG. 3 illustrates the effect of intravitreous administration 
of poly (I:C) on activated caspase-3 expression in retinal 
pigmented epithelial cells from Wild-type and Tlr3"/+ mice. 
FIG. 4 shoWs the effect of intravitreous administration of 
poly (I:C), poly (I:CIZU) and poly (dI:dC) on choroidal 
neovasculariZation (CNV) in Tlr3"/+ and Tlr3_/_ mice. 
FIG. 5 illustrates the effect of 9 to 23 nucleotide versions of 
siRNA-Luc on CNV in Wild-type mice. 
FIG. 6 shoWs the effect of 21-nt siRNA-Luc and 21-nt 
dsDNA on the ability of 23-nt siRNA-Luc to suppress CNV in 
Wild-type mice. 
FIG. 7 illustrates ability of 2'O-methyl-21-nt siRNA-Luc 
cholesterol, 2'O-methyl-18-nt siRNA-Luc-cholesterol, and 
2'O-methyl-15-nt siRNA-Luc-cholesterol to rescue human 
retinal pigmented epithelial cells from poly (I:C) induced 
cytotoxicity. 
FIG. 8 shoWs immunohistochemistry using a monoclonal 
anti-long dsRNAAb (J 2), Which reveals blue reaction product 
in drusen (arrow), RPE, Bruch’s membrane and choriocapil 
laris (asterisk, collectively) in a donor eye of an 84-year-old 
patient With GA (a). Isotype control Ab revealed no speci?c 
immunostaining in another region of the same eye (b). J2 did 
not stain the retina or choroid of a 78-year-old patient Without 
AMD (c). Images are representative of 5-7 eyes per group. 
FIG. 9 provides color fundus photographs shoWing that 
intravitreous administration of Ampligen® (poly I:C12U; 2 
pg), a double stranded RNA that speci?cally activates TLR3, 
induces retinal degeneration (arroWs) in Wild-type C57Bl/6J 
mice (left panel) but not in TLR3 —/— mice (right panel). The 
photographs Were taken 10 days after Ampligen® injection. 
FIG. 10 provides color fundus photographs shoWing that 
intravitreous administration of Ampligen® (poly I:C12U; 2 
pg) in Wild-type mice does not cause retinal degeneration 
When neutraliZing anti-TLR3 antibody (eBioscience; 12 pg) 
is co-administered (left panel). It Was further shoWn that 
isotype control antibody (IgG; Jackson Immunoresearch; 12 
US 8,481,508 B2 
3 
pg) does not block the effects of Ampligen® (right panel). 
The photographs Were taken 10 days after Ampligen® and 
antibody injection. 
FIG. 11 provides color fundus photographs showing that 
retinal degeneration induced by intravitreous administration 
of Ampligen® (poly I:Cl2U; 2 pg) in Wild-type mice (left 
panel) does not occur When blunt end double stranded 5-nt 
dsRNA conjugated to cholesterol (chol) is co-administered 
(right panel). The photographs Were taken 10 days afterAmp 
ligen® and 5-nt-dsRNA injection. 
FIG. 12 provides color fundus photographs shoWing that 
retinal degeneration induced by intravitreous administration 
of Ampligen® (poly I:Cl2U; 2 pg) in Wild-type mice (left 
panel) does not occur When blunt end double stranded 7-nt 
dsRNA (4 pg) conjugated to cholesterol (chol) is co-admin 
istered (right panel). The photographs Were taken 10 days 
after Ampligen® and 7-nt-dsRNA injection. 
FIG. 13 provides color fundus photographs shoWing that 
retinal degeneration induced by intravitreous administration 
of Ampligen® (poly I:Cl2U; 2 pg) in Wild-type mice (left 
panel) does not occur When cholesterol (chol)-conjugated 
double stranded l6-nt-dsRNA (8 pg), Which contains 14 base 
pairs on each strand With 2-nt overhangs on each strand, is 
co-administered (right panel). The photographs Were taken 
10 days after Ampligen® and l6-nt-dsRNA injection. 
FIG. 14 provides transmission electron micrographs shoW 
ing that intravitreous administration of Ampligen® (poly 
I:Cl2U; 2 pg) in Wild-type mice (left panels) results in pho 
toreceptor outer segment (POS) damage (red arroWheads; top 
left) and degeneration of retinal pigmented epithelial (RPE) 
cells in Wild-type mice. Co-administration of l6-nt-dsRNA 
chol (8 pg) preserves the anatomical architecture of the POS 
and RPE. The images Were taken 2 Weeks after drug admin 
istration. 
FIG. 15 provides scotopic electroretinograms (ERG) 
shoWing that a-Wave amplitude is attenuated by intravitreous 
administration of Ampligen® (poly I:Cl2U; 2 pg) in Wild 
type mice, as compared to phosphate buffered saline (PBS). 
Co-administration of 16 nt-dsRNA-chol (8 pg) rescued the 
ERG a-Wave attenuation. 
FIG. 16 shoWs that double stranded RNA requires a cell 
permeating entity for intemaliZation by mammalian cells. 
Mouse endothelial cell cultures Were exposed to ?uorescein 
conjugated dsRNA (Fl-dsRNA) folloWed by time-lapse con 
focal microscopy (left panel, Nomarski, right panel, green 
channel). When Fl-dsRNA Was conjugated With cholesterol 
(Fl-dsRNA Chol), a cell-permeant entity, there Was robust 
LEC internalization. 
DETAILED DESCRIPTION 
Toll-like receptors (TLRs) are type I transmembrane pro 
teins involved in innate immunity by recogniZing microbial 
conserved structures. Toll-like receptors can help activate the 
adaptive immune response, thereby linking innate and 
acquired immune responses. Ten TLRs (named TLRl to 
TLRlO) have been identi?ed in humans, With each TLR being 
speci?c for a different microbial-associated molecular pat 
tern. The present inventor has surprisingly found that double 
stranded RNAs of 22 nucleotides (nt) or shorter lengthbind to 
but do not activate toll-like receptor-3 (TLR3) and, among 
other things, can inhibit the geographic atrophy of macular 
degeneration. 
In one aspect, methods and compositions are provided for 
the treatment or prevention of macular degeneration, includ 
ing geographic atrophy of macular degeneration such as the 
geographic atrophy of dry macular degeneration. For 
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example, administration of antagonists of TLR3 inhibits the 
geographic atrophy of macular degeneration such as the geo 
graphic atrophy of dry macular degeneration. Geographic 
atrophy includes choroidal atrophy and retinal atrophy. Com 
positions and methods for blocking the activity of TLR3 for 
the treatment and/ or prevention of macular degeneration are 
provided. 
Any double-stranded RNA of 22 nucleotides or shorter 
length Which binds to but does not activate TLR3 may be used 
in the present invention. Natural agonists for TLR3 include 
viral double-stranded RNA. Any natural agonist of TLR3 can 
be converted to an antagonist by shortening the length to 22 
nucleotides or less. Such shortened double-stranded RNAs 
bind to but do not activate TLR3 activity. Preferably, the 
length of the double-stranded RNA is 5-22 nucleotides. Pref 
erably, the length of the double-stranded RNA is 5-15 nucle 
otides. More preferably, the length is 7-11 nucleotides. 
In addition, other ligands can also be used to antagonize 
TLR3 activity. Such ligands include sequence-speci?c (or 
targeted) and sequence-nonspeci?c (or non-targeted) double 
stranded RNA having a length of 22 nucleotides or less. The 
double stranded RNA can be an siRNA, or any other double 
stranded RNA, as long as the length is 22 nucleotides or less. 
While the constructs containing the double-stranded RNA are 
effective When made With either blunt ends or With overhangs, 
if overhangs are used the nucleotides comprising the over 
hangs are considered part of 22 or less total nucleotides. 
Thus, a double stranded RNA of 22 nucleotides or shorter 
the length includes those RNAs Which contain some single 
stranded portion as long as a majority of the molecule has a 
double stranded RNA structure. Such double stranded RNAs 
include RNAs Which have a double stranded central portion 
and having 3' overlaps of l, 2, 3 or more nucleotides on the 
sense strand or antisense strand or both, such as overlaps of 
dT residues. The length of all single stranded and double 
stranded regions are added to determine the overall length of 
the double stranded RNA. For example, a double stranded 
RNA having a 16 nucleotide central double stranded RNA 
structure and 3' overlaps of dTdT on both the sense and 
antisense strands Would have an overall length of 20 nucle 
otides. Double stranded RNAs are also contemplated Which 
have one or more internal nucleotides Which do not have a 
base pair. Double stranded RNAs also include those RNAs 
With no single stranded regions at all, such as a blunt end 
double stranded RNA of 22 nucleotides or less. 
The siRNAs for use in the present invention are designed 
according to standard methods in the ?eld of RNA interfer 
ence. Introduction of siRNAs into cells may be by transfec 
tion With expression vectors, by transfection With synthetic 
dsRNA, or by any other appropriate method. Transfection 
With expression vectors is preferred. Alternatively, the cell 
exterior can be exposed to a composition containing the siR 
NAs of the present invention. 
The expression vectors Which can be used to deliver siRNA 
according to the invention include retroviral, adenoviral and 
lentiviral vectors. The expression vector includes a sequence 
Which codes for a portion of a target gene or any other 
sequence Whether speci?c for a particular gene or a nonsense 
sequence. The gene sequence is designed such that, upon 
transcription in the transfected host, the RNA sequence forms 
a hairpin structure due to the presence of self-complementary 
bases. Processing Within the cell removes the loop resulting in 
formation of a siRNA duplex. The double stranded RNA 
sequence should be less than 23 nucleotides; preferably the 
dsRNA sequence is 15-22 nucleotides in length; more pref 
erably the dsRNA sequence is 21 nucleotides in length, or 18 






